These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
113 related articles for article (PubMed ID: 17026456)
1. CXC chemokines and prostate cancer: growth regulators and potential biomarkers. Lentsch AB Future Oncol; 2006 Oct; 2(5):651-8. PubMed ID: 17026456 [TBL] [Abstract][Full Text] [Related]
2. The role of CXC chemokines and their receptors in cancer. Vandercappellen J; Van Damme J; Struyf S Cancer Lett; 2008 Aug; 267(2):226-44. PubMed ID: 18579287 [TBL] [Abstract][Full Text] [Related]
4. The Duffy antigen/receptor for chemokines (DARC) and prostate cancer. A role as clear as black and white? Lentsch AB FASEB J; 2002 Jul; 16(9):1093-5. PubMed ID: 12087071 [TBL] [Abstract][Full Text] [Related]
5. Progressive dysregulation of transcription factors NF-kappa B and STAT1 in prostate cancer cells causes proangiogenic production of CXC chemokines. Shen H; Lentsch AB Am J Physiol Cell Physiol; 2004 Apr; 286(4):C840-7. PubMed ID: 14656722 [TBL] [Abstract][Full Text] [Related]
6. Prostate tumor CXC-chemokine profile correlates with cell adhesion to endothelium and extracellular matrix. Engl T; Relja B; Blumenberg C; Müller I; Ringel EM; Beecken WD; Jonas D; Blaheta RA Life Sci; 2006 Mar; 78(16):1784-93. PubMed ID: 16263140 [TBL] [Abstract][Full Text] [Related]
7. Dose-dependent effect of radiation on angiogenic and angiostatic CXC chemokine expression in human endothelial cells. Chang CC; Lerman OZ; Thanik VD; Scharf CL; Greives MR; Schneider RJ; Formenti SC; Saadeh PB; Warren SM; Levine JP Cytokine; 2009 Dec; 48(3):295-302. PubMed ID: 19782578 [TBL] [Abstract][Full Text] [Related]
8. Breast tumor cell soluble factors induce monocytes to produce angiogenic but not angiostatic CXC chemokines. Toulza F; Eliaou JF; Pinet V Int J Cancer; 2005 Jun; 115(3):429-36. PubMed ID: 15688373 [TBL] [Abstract][Full Text] [Related]
9. Monitoring serum levels ELR+ CXC chemokines and the relationship between microvessel density and angiogenic growth factors in multiple myeloma. Pappa CA; Tsirakis G; Kanellou P; Kaparou M; Stratinaki M; Xekalou A; Alegakis A; Boula A; Stathopoulos EN; Alexandrakis MG Cytokine; 2011 Dec; 56(3):616-20. PubMed ID: 21940178 [TBL] [Abstract][Full Text] [Related]
10. Association between lack of angiogenic response in muscle tissue and high expression of angiostatic ELR-negative CXC chemokines in patients with juvenile dermatomyositis: possible link to vasculopathy. Fall N; Bove KE; Stringer K; Lovell DJ; Brunner HI; Weiss J; Higgins GC; Bowyer SL; Graham TB; Thornton S; Grom AA Arthritis Rheum; 2005 Oct; 52(10):3175-80. PubMed ID: 16200621 [TBL] [Abstract][Full Text] [Related]
11. The expression and role of CXC chemokines in colorectal cancer. Verbeke H; Struyf S; Laureys G; Van Damme J Cytokine Growth Factor Rev; 2011; 22(5-6):345-58. PubMed ID: 22000992 [TBL] [Abstract][Full Text] [Related]
12. Overexpression of the duffy antigen receptor for chemokines (DARC) by NSCLC tumor cells results in increased tumor necrosis. Addison CL; Belperio JA; Burdick MD; Strieter RM BMC Cancer; 2004 Jun; 4():28. PubMed ID: 15214968 [TBL] [Abstract][Full Text] [Related]
13. Pleiotropic functions of the CXC-type chemokine CXCL14 in mammals. Hara T; Tanegashima K J Biochem; 2012 May; 151(5):469-76. PubMed ID: 22437940 [TBL] [Abstract][Full Text] [Related]
14. Interaction of ligand-receptor system between stromal-cell-derived factor-1 and CXC chemokine receptor 4 in human prostate cancer: a possible predictor of metastasis. Mochizuki H; Matsubara A; Teishima J; Mutaguchi K; Yasumoto H; Dahiya R; Usui T; Kamiya K Biochem Biophys Res Commun; 2004 Jul; 320(3):656-63. PubMed ID: 15240098 [TBL] [Abstract][Full Text] [Related]
15. The role of proinflammatory cytokines and CXC chemokines (CXCL1-CXCL16) in the progression of prostate cancer: insights on their therapeutic management. Ullah A; Jiao W; Shen B Cell Mol Biol Lett; 2024 May; 29(1):73. PubMed ID: 38745115 [TBL] [Abstract][Full Text] [Related]
16. Understanding the immunoangiostatic CXC chemokine network. Balestrieri ML; Balestrieri A; Mancini FP; Napoli C Cardiovasc Res; 2008 May; 78(2):250-6. PubMed ID: 18252760 [TBL] [Abstract][Full Text] [Related]
17. Modulation of CXCL14 (BRAK) expression in prostate cancer. Schwarze SR; Luo J; Isaacs WB; Jarrard DF Prostate; 2005 Jun; 64(1):67-74. PubMed ID: 15651028 [TBL] [Abstract][Full Text] [Related]
18. CXC chemokines: angiogenesis, immunoangiostasis, and metastases in lung cancer. Strieter RM; Belperio JA; Burdick MD; Sharma S; Dubinett SM; Keane MP Ann N Y Acad Sci; 2004 Dec; 1028():351-60. PubMed ID: 15650260 [TBL] [Abstract][Full Text] [Related]
19. CCR1 chemokines promote the chemotactic recruitment, RANKL development, and motility of osteoclasts and are induced by inflammatory cytokines in osteoblasts. Yu X; Huang Y; Collin-Osdoby P; Osdoby P J Bone Miner Res; 2004 Dec; 19(12):2065-77. PubMed ID: 15537451 [TBL] [Abstract][Full Text] [Related]
20. Distinct CXC chemokines mediate tumorigenicity of prostate cancer cells. Moore BB; Arenberg DA; Stoy K; Morgan T; Addison CL; Morris SB; Glass M; Wilke C; Xue YY; Sitterding S; Kunkel SL; Burdick MD; Strieter RM Am J Pathol; 1999 May; 154(5):1503-12. PubMed ID: 10329603 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]